What Should US Policymakers Learn From International Drug Pricing Transparency Strategies?

Nagar, Sarosh; Rand, Leah Z; Kesselheim, Aaron S

Nagar, Sarosh; Rand, Leah Z; Kesselheim, Aaron S.

Afiliação

Nagar S; Research assistant in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics of Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.
Rand LZ; Research scientist in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics of Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.
Kesselheim AS; Professor of medicine at Harvard Medical School and director of the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics of Harvard Medical School and Brigham and Women's Hospital in Boston, Massachusetts.

AMA J Ethics ; 24(11): E1083-1090, 2022 11 01.

Article em En | MEDLINE | ID: mdl-36342492

Assuntos

Custos de Medicamentos; Medicamentos sob Prescrição; Humanos; Estados Unidos; Custos e Análise de Custo; Reino Unido; Canadá

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos de Medicamentos / Medicamentos sob Prescrição Tipo de estudo: Health_economic_evaluation Limite: Humans País/Região como assunto: America do norte / Europa Idioma: En Revista: AMA J Ethics Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google